Double malignancy and a mycobacterial infection in a rheumatoid arthritis patient

References

1. 1.↵
   1. Askling J,
   2. Dixon W.

   The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008; 20: 138–144.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Carmona L,
   2. Hernández-García C,
   3. Vadillo C,
   4. Pato E,
   5. Balsa A,
   6. González-Alvaro I, et al.

   Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003; 30: 1436–1439.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Baecklund E,
   2. Iliadou A,
   3. Askling J,
   4. Ekbom A,
   5. Backlin C,
   6. Granath F, et al.

   Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006; 54: 692–701.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Amari W,
   2. Zeringue AL,
   3. McDonald JR,
   4. Caplan L,
   5. Eisen SA,
   6. Ranganathan P.

   Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology (Oxford) 2011; 50: 1431–1439.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Askling J,
   2. Fored CM,
   3. Brandt L,
   4. Baecklund E,
   5. Bertilsson L,
   6. Feltelius N, et al.

   Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1421–1426.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Boussios S,
   2. Pentheroudakis G,
   3. Somarakis G,
   4. Markatseli TE,
   5. Drosos AA,
   6. Pavlidis N.

   Cancer diagnosis in a cohort of patients with Sjogren’s syndrome and rheumatoid arthritis: a single-center experience and review of the literature. Anticancer Res 2014; 34: 6669–6676.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Kune GA,
   2. Kune S,
   3. Watson LF.

   Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48: 4399–4404.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Huss V,
   2. Bower H,
   3. Wadström H,
   4. Frisell T,
   5. Askling J.

   Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice. Rheumatology (Oxford) 2022; 61: 1810–1818.

   OpenUrl
9. 9.↵
   1. Campbell L,
   2. Chen C,
   3. Bhagat SS,
   4. Parker RA,
   5. Östör AJ.

   Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford) 2011; 50: 552–562.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Mélet J,
    2. Mulleman D,
    3. Goupille P,
    4. Ribourtout B,
    5. Watier H,
    6. Thibault G.

    Rituximab-induced T cell depletion in patients with rheumatoid arthritis: Association with clinical response. Rheumatoid Arthritis 2013; 65: 2783–2790.

    OpenUrl